Kornimate/medical-research-clean huggingface dataset:
use of methoxyflurane (penthrox) as an antalgic in hospital trauma

Conditions: Pain; Traumatic Injury

Summary: study of traumatized patients treated in emergency departments of tours, seeking to optimize the management of trauma pain in an inpatient setting, with the opportunity to integrate inhaled methoxyflurane (penthrox®) into the arsenal analgesics useful in the analgesic protocol of the reception and orientation nurse.

intra-hospital, the prevalence of pain is major; this is variable depending on the studies, but permanently above 60%. a study conducted in 2015 in tours adult emergencies showed a prevalence of pain of 66.5% with an average waiting time of 2h28 before receiving an analgesic. the pain management protocol at the tours emergency department includes paracetamol for a numerical evaluation scale (en) \< 3 and tramadol for an en between 4 and 6. but these therapies have a delay of action too long or are given too late. an improvement in the management of pain in emergency is therefore necessary. methoxyflurane (penthrox®) is a volatile fluoridated analgesic; it offers several benefits: fast over a long period, well tolerated, effective and without interference with other drugs. despite a misuse in the 70s, it has been used for more than 20 years in australia and new zealand. it was granted marketing authorization in 2016 and has been marketed in france since 2017. it should be noted that this analgesic treatment is already adopted in several hospitals in the region and also in the samu 37. a similar study was conducted in grenoble but on a different population. the investigators plan to highlight the interest of penthrox® in the management of monotraumatic pains in the adult emergencies of tours with the intention of modifying the antalgic protocol accordingly to the reception of emergencies.

Eligibility criteria:
inclusion criteria: * conscious patient * age ≥ 18 years * acute pain of monotraumatic origin * pain \> 4 on a visual numerical scale exclusion criteria: * state of shock with unstable hemodynamics (pa \<90/60) * suspected or proven trauma to the chest, abdomen or pelvis * serious head trauma * consciousness disorder with glasgow score \<15 * patient who has already received analgesics (with the exception of paracetamol) * patient receiving an intravenous approach for analgesia * renal or hepatic disorders known * hypersensitivity to fluoridated anesthetics or history of malignant hyperthermia in the patient or family * pregnant or nursing woman * patient under judicial protection * non communicating patient or with difficulties of understanding exclusion criteria: * intravenous injection for analgesia

Keywords: methoxyflurane penthrox non opioid analgesia traumatic pain pain antalgic protocol emergency department
echocardiographic markers of atrial fibrillation recurrence post radiofrequency ablation

Conditions: Atrial Fibrillation

Summary: determine echocardiographic predictors of atrial fibrillation recurrence post radiofrequency ablation and evaluate markers of low voltage areas on 3d mapping.


Eligibility criteria:
inclusion criteria: * paroxysmal or persistent ablation exclusion criteria: * previous af ablation * previous left atrial ablation * refusal to give informed consent * congenital cradiomiopathy

Keywords: atrial fibrillation radiofrequency ablation
effect of traditional chinese medicine on gi function recovery and nutrition support in sap

Conditions: Pancreatitis, Acute Necrotizing

Summary: with multicenter randomized control clinical evaluation investigations, the effect of traditional chinese medicine on gastrointestinal function recovery and nutrition support in early stage of severe acute pancreatitis (sap) was evaluated, and the therapeutic effects, safety and indications assured. drawing in latest research fruits at home and abroad, a clinical practical guideline would be formed, to be popularized all over china.


Eligibility criteria:
inclusion criteria: * adult patients 18 yr-70 yr * complying with the diagnostic standard of acute pancretitis (clinical symptoms and signs, elevated blood and urine amylase, and imaging criteria) * conforming to 3 or more ranson's criteria and apache-ii score larger than 8, balhazar ct score larger than 5 exclusion criteria: * pregnancy * nursing mother * critical cases of advanced tumor * on the verge of death (estimated to be moral in 12h) * severe visceral function disturbance * patients undergoing other therapeutic research that might interfere with the present study
mindfulness-based treatment to prevent smoking relapse

Conditions: Smoking Cessation

Summary: background: smoking causes a variety of health problems and causes burden to healthcare systems. even when support is provided, local data suggest that around 50% of biochemically confirmed quitters resume smoking within 6 months of participating in a smoking cessation program. mindfulness-based intervention is a promising option because accumulating evidence from randomized controlled trials support its use among smokers. our team aims to determine if mindfulness-based interventions can prevent relapse in smokers who recently quit smoking. a pilot trial is needed to determine the feasibility of recruitment, randomisation and acceptability of the intervention in these patients method: forty participants, who just quitted smoking, will be randomised in a 1:1 ratio to the 8week mindfulness-based relapse prevention (mbrp) program and to usual care.


Eligibility criteria:
inclusion criteria: * age ≥18 years * self-reported smokers * can speak and read cantonese and chinese * willing to participate in at least 7 of the 8 sessions of the mbrp program exclusion criteria: * pregnancy (they will have different motivations for quitting smoking) * significant physical illness or severe cognitive impairment that prevents communication, such as blindness or severe hearing loss, because mindfulness exercise instructions are given verbally and reading materials are given out after each class * history of psychotic disorders or symptoms, because mbrp is not confirmed safe or effective in this group of patients * suicidal tendency as detected by phq-9 (see below) * we will not exclude participants with mood disorders for the reasons stated in the introduction, but participants with drug changes for their mood disorders in the last 3 months will be excluded (ethics approval and informed consent will be obtained for assessing patients' medical records, cms of the hospital authority or e-health, to confirm drug information) * active illicit drug use and * past mindfulness course or practices in the previous 12 months
study of pharmacodynamic effects of vay736 in patients with primary sjögren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: this study consists of three consecutive parts. part 1 in primary sjögren's syndrome (pss) patients (n=2-6) and part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected \[zr-89\]-rituximab pet/ct method is a valid method to assess b cells in salivary glands of pss patients. in part 1 and part 2 no imp will be applied to the subjects. in part 3, pss patients (n=12) will receive the imp, vay736. posted information will be focused on part 3. the overarching purpose of this study is to test a new drug (vay736) for the treatment of pss. in pss, the salivary glands (the glands that produce saliva) and other organs are affected by inflammation. a certain type of white blood cells called b cells prominently infiltrate the salivary glands in pss, whereas they are not present in healthy salivary glands. scientific evidence suggests that b cells may be involved in the disease process in pss and that eliminating b cells may benefit patients with pss. this study will test a new imaging method and a new treatment for pss. both the imaging method and the treatment are specific for b cells.


Eligibility criteria:
part 1 and 3: inclusion criteria: * fullfilled consensus criteria for primary sjögren's syndrome * patients must have elevated serum levels for some sögren syndorme specific parameters such as antinuclear antibodies (ana), rheumatoid factor (rf) etc. exclusion criteria: * patients that are suffering from secondary sjögren's syndrome. * patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc. part 2 inclusion criteria: - healthy male and female people 18-75 years of age exclusion criteria: * use of other investigational drugs at the time of enrollment * exposure to a sizeable degree of radiation (≥ 5 msv) in an investigational research study in the past year prior to this study

Keywords: primary sjögren's syndrome sicca syndrome salivary glands positron emission tomography b cell depletion
biology of young lung cancer study: the young lung study

Conditions: Non Small Cell Lung Cancer; Small Cell Lung Carcinoma; NUT Carcinoma

Summary: the purpose of this research study is to learn more about lung cancer (nsclc or sclc) diagnosed in adults at ages 45 or younger.

this research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to: * better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease * better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger * examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients * improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger study procedures will include: * collecting information from participants' medical record and two (2) short questionnaires * collecting blood and/or saliva samples * collecting tumor tissue samples (optional) it is expected that about 500 people will take part in this research study. participants will be in this study until it closes or the participant withdraws consent.

Eligibility criteria:
inclusion criteria: * age 45 and under at lung cancer diagnosis * pathologically confirmed bronchogenic lung carcinoma (nsclc or sclc of any stage) at any treatment time point * provision of written informed consent * willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks * individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent exclusion criteria: * individuals who decline to sign consent * individuals who are unable to give consent or assent and are without a designated healthcare proxy * compromise of patient diagnosis or staging if tissue is used for research

Keywords: non small cell lung cancer small cell lung carcinoma genetics genomics young lung cancer
rsyr for fatigue reduction in cancer fatigue caused by chemotherapy

Conditions: Cancer-related Problem/Condition

Summary: this is a multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of chinese herbal compound in improving fatigue symptoms and quality of life in patients with chemotherapy.

in this study, symptomatic indicators and quality of life were used as the main evaluation indicators. patients with moderate to severe crf who received dual drug chemotherapy were given traditional chinese medicine compound and placebo intervention respectively. the data of fatigue symptoms, quality of life, sleep quality, blood routine test, liver and kidney function were observed and compared, so as to verify the traditional chinese medicine compound prescription in improving the crf symptoms and quality of life of chemotherapy patients validity.

Eligibility criteria:
inclusion criteria: * malignant tumor patients with pathological diagnosis * men and women aged 18-75 * kps score ≥ 70, expected survival time more than 6 months * the function of heart, lung, liver and kidney was normal * hemoglobin ≥ 8g * neuroendocrine function is normal * bmi ≥ 18.5. * cancer pain, vas score \< 3 * fatigue score ≥ 4 * syndrome differentiation is deficiency of qi and blood exclusion criteria: * brain metastases with symptomatic * mental disease * severe infection * insomniacs * pregnant or lactating women

Keywords: chemotherapy fatigue cancer
a study of guselkumab for the treatment of participants with crohn's disease after surgical resection

Conditions: Crohn's Disease

Summary: the purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of crohn's disease in participants after surgery.


Eligibility criteria:
inclusion criteria: * have a documented diagnosis of crohn's disease (cd) confirmed by endoscopic, histologic, and/or radiologic studies prior to resection or by tissue obtained at resection * have undergone an ileocolonic surgical resection (that is, an intestinal resection with an ileocolonic anastomosis) for cd prior to the baseline visit with the following criteria: (a)have no known active cd anywhere in the gastrointestinal (gi) tract, including the findings at surgery. (b)be able to undergo randomization no later than 49 days after surgery, and at least 10 days after surgery (or 8 days after resumption of bowel activity, example, in case of postoperative ileus) (c) ileocolonic resection was not for the purpose of removing known dysplasia. (d) if ileocolonic resection is the participant's first resection for crohn's, and occurs greater than (\>) 10 years since the diagnosis of cd and only fibrostenotic stricturing is present, then length of stricture must be \> 10 centimeter (cm) * have a baseline crohn's disease activity index (cdai) less than (\<) 200 * a woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hcg\]) test result during screening and a negative urine pregnancy test at week 0, prior to randomization * a woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 12 weeks after the last administration of study intervention exclusion criteria: * has complications of cd, such as symptomatic strictures or stenoses, short bowel syndrome, a draining (that is, functioning) stoma or ostomy, or any other manifestation, that might be anticipated to require surgery, could preclude the use of the cdai to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab * currently has or is suspected to have an abscess. recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before baseline, or 8 weeks before baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery * have had any active perianal disease within 3 months of screening (except skin tags) or have had any draining fistula within 3 months of screening unless the fistula was removed at the index surgery * evidence of a herpes zoster infection within 8 weeks before the first dose of study intervention * has a history of severe, progressive, or uncontrolled renal, genitourinary, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof

Keywords: endoscopy, postoperative, ileocolonic resection
comparison of desloratadine associated with prednisolone oral solution versus dexchlorpheniramine associated with betamethasone for persistent allergic rhinitis treatment

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of moderate - severe persistent allergic rhinitis.

* double-blind, non-inferiority, prospective, parallel group trial. * experiment duration: 07 days. * 02 visits (days 0 and 7). * efficacy will be evaluated for persistent allergic rhinitis based on nasal symptoms score * adverse events evaluation.

Eligibility criteria:
inclusion criteria: * consent of the patient or legal guardian; * clinical diagnosis of moderate - severe persistent allergic rhinitis according to the classification of aria (allergic rhinitis and its impact on asthma); * children aged between 2 and 11 years and 11 months (up to 30 kg); * presence of nasal symptoms score greater than or equal to 5 (scale 0 to 12)in the last week; * evidence of sensitization to aeroallergens in examination (immediate skin tests or serum specific ige) in the 12 months prior to inclusion. exclusion criteria: * participation in clinical trial in 30 days prior to study entry; * patients receiving immunotherapy; * patients with history of hypersensitivity to desloratadine or prednisolone or with corticosteroids use contraindications ; * patients with any clinically significant disease other than allergic rhinitis, including hematopoietic, cardiovascular, renal, neurological, psychiatric or autoimmune disorders; * patients on treatment with monoamine oxidase inhibitors (maois); * patients who were in use of oral antihistamines or decongestants in the past 15 days; * patients who were treated with systemic corticosteroids in the last month; * patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and nasal anatomic abnormalities.
the prenaps study: fi, nutrition, and psychosocial health outcomes at gulu regional referral hospital

Conditions: HIV; Pregnancy

Summary: the prenatal nutrition and psychosocial health outcomes (prenaps) study was a two year collaboration between gulu, makarere, cornell, and tufts universities. the prenaps study's primary goals were: a) to determine the differential impacts of food insecurity on gestational weight gain and prenatal depression, and b) to elucidate the mechanisms underlying the relationship between food insecurity and weight gain and/depression among hiv infected and hiv uninfected pregnant women in gulu, northern uganda.


Eligibility criteria:
inclusion criteria: * pregnant women * known hiv status * receiving antiretroviral therapy (if hiv-infected) * attending antenatal care at gulu regional referral hospital * \>18 years of age exclusion criteria: * pregnant women \<18 years of age * unknown hiv status * not receiving antiretroviral therapy (if hiv-infected) * not attending antenatal care at gulu regional referral hospital

Keywords: food insecurity nutrition
clinicopathological features and genetic susceptibility screening of recurrent drug-induced liver injury

Conditions: Recurrent Drug-induced Liver Injury

Summary: the goal of this observational study is to screening for clinical, pathological and hla features in patients with recurrent drug-induced liver injury. the main question it aims to answer is: which patients with drug-induced liver injury need to be more cautious when re-dosing?

research objectives: 1. to summarise the clinicopathological characteristics of patients with recurrent drug-induced liver injury (dili) in the liver disease centre of beijing friendship hospital in the past 10 years. 2. compare the differences in clinicopathological characteristics between patients with only one episode of different drug use and those with recurrent dili, and predict the risk/protective factors in patients with recurrent dili. 3. explore the susceptibility genes in patients with recurrent dili.

Eligibility criteria:
inclusion criteria: * inclusion criteria for recurrent drug induced liver injury: 1. liver enzymes returns to normal or has a tendency to remission after the first drug liver injury; 2. signs and symptoms of liver injury after the patient takes the different drugs for liver injury again, and the liver enzymes returns to normal through follow-up. inclusion criteria for drug induced liver injury: 1. rucam ≥6 and met one of the following biochemical conditions: (1)alt≥5 uln, (2) or alp ≥2 uln, (3) or alt≥3 uln and tbil≥2 uln. 2. rucam between 3-5, five experienced hepatologists in leading site evaluate and vote the diagnosis of dili, the case would be enrolled if only ≥4 out of 5 hepatologists agree with the diagnosis. 3. onset to enrollment ≤3 months. exclusion criteria: * 1. hepatotropic viral infection: hepatitis a, b, c, d and e. 2. non-hepatotropic viral infection: cytomegalovirus (cmv) and epstein-barr virus (ebv), etc. 3. hypoxic ischemic hepatitis and congestive liver disease. 4. alcohol consumption: male \>40g/d, female \>20g/d, and ≥5 years.5. biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. autoimmune hepatitis: international autoimmune hepatitis group (iahg)simplified score ≥6 or complicated score ≥10, or differentiation from autoimmune hepatitis is impossible during enrollment. 7. parasitic infection. 8. sepsis. 9. previous liver transplantation or bone marrow transplantation. 10. pregnancy or lactation. 11. genetic and metabolic liver diseases.

Keywords: genetic susceptibility hla endpoint event(s) drug-induced liver injury
"reversibility of cardiovascular injury with cpap use: mechanisms involved"

Conditions: Sleep Apnea, Obstructive; Hypoxia; Hypercapnia; Sleep Disorders; Obesity; Hypertension; Coronary Artery Vasospasm; Right Ventricular Overload; Left Ventricular Function Systolic Dysfunction; Ventricular Hypertrophy

Summary: the purpose of this study is to determine the factors that are associated with improved cardiovascular function with the use of cpap therapy on subjects diagnosed with moderate to severe obstructive sleep apnea.

we will monitor non-invasively changes in arterial stiffness, cardiac mass, pulmonary pressures, endothelial function, etc. we will also assess the reversibility of these changes after only 5-7 days of not using the cpap mask. in a subgroup of subjects we will explore changes in coronary flow response after 12 weeks of cpap use compared with baseline.

Eligibility criteria:
inclusion criteria: * subjects naïve of cpap therapy just recently diagnosed with moderate to severe obstructive sleep apnea (osa). the degree of osa is defined by results of a comprehensive polysomnogram requiring an apnea hypopnea index (ahi) \>15 events/hour and epworth score \>10, or an ahi \>20 events/hour * either sex * any race * between 21-50 years old. exclusion criteria: * systolic blood pressure \>160 mmhg, or diastolic blood pressure \>100 mmhg * changes in antihypertensive medications in the last 6 weeks * restless leg syndrome * average overnight oxygen saturation below 80% * current use of beta-blockers * history of coronary artery disease * history of stroke * atrial fibrillation * peripheral vascular disease * suspected cardiac valve abnormality * ejection fraction \<50% * type i and type ii diabetes mellitus (dm) * asthma or confirmed chronic obstructive pulmonary disease * cigarette smoking in the last 6 months * raynaud's disease * pregnancy (the normal hormonal changes that occur in pregnancy affect greatly arterial stiffness parameters) if a subject becomes pregnant we will discontinue data collection. * physically incapable of resting on left lateral decubitus for 40 minutes. * mastectomy with lymph node removal that might preclude us to monitor blood pressures on both arms